ADReCS

Pharmaceutical Information

Drug Name	Prednisolone
Drug ID	BADD_D01831
Description	Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage	Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status	approved; vet_approved
ATC Code	A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID	DB00860
KEGG ID	D00472
MeSH ID	D011239
PubChem ID	5755
TTD Drug ID	D0D1SG
NDC Product Code	38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII	9PHQ9Y1OLM
Synonyms	Prednisolone \| Predate \| Predonine \| Di-Adreson-F \| Di Adreson F \| DiAdresonF

Chemical Information

Molecular Formula	C21H28O5
CAS Registry Number	50-24-8
SMILES	CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Bone marrow failure	01.03.03.005	0.000157%
Soft tissue necrosis	15.03.02.002; 24.04.02.007	0.000035%
Central obesity	14.03.02.011	0.000122%		Not Available
Chronic graft versus host disease	12.02.09.003; 10.02.01.029	0.000070%		Not Available
Tendon pain	15.07.01.009	0.000087%		Not Available
Treatment failure	08.06.01.017	0.001307%		Not Available
Organising pneumonia	22.01.02.008	0.000070%		Not Available
Low birth weight baby	18.04.02.003	0.000979%		Not Available
Type 1 diabetes mellitus	14.06.01.010; 10.04.08.007; 05.06.01.010	0.000105%		Not Available
Epidural lipomatosis	17.10.01.012; 14.08.04.019	0.000122%		Not Available
Gastrointestinal sounds abnormal	07.01.01.002	0.000052%		Not Available
Focal segmental glomerulosclerosis	20.05.01.003	0.000070%		Not Available
Skin mass	23.07.04.014	0.000105%		Not Available
Brain injury	19.07.03.007; 17.11.01.003	0.000052%		Not Available
Cholestatic liver injury	09.01.07.016	0.000052%		Not Available
Intellectual disability	19.21.06.001; 17.03.07.001	0.000035%		Not Available
Hypertransaminasaemia	09.01.02.005	0.000035%		Not Available
Epstein-Barr virus associated lymphoproliferative disorder	16.21.02.002; 01.13.02.002; 11.05.10.001	0.000052%		Not Available
Neurological decompensation	17.02.05.030	0.000052%		Not Available
Kounis syndrome	24.04.04.020; 10.01.03.037; 02.02.02.020	0.000070%		Not Available
Hypoxic-ischaemic encephalopathy	17.13.02.006; 24.04.06.021; 22.02.02.011	0.000035%		Not Available
Foetal growth restriction	18.03.01.002	0.000419%
Gestational hypertension	24.08.07.004; 18.02.03.004	0.000087%		Not Available
Posterior reversible encephalopathy syndrome	17.13.02.007	0.000524%
Macular fibrosis	06.09.03.014	0.000280%		Not Available
Substance-induced psychotic disorder	19.03.01.007; 12.03.01.053	0.000559%		Not Available
Granulomatosis with polyangiitis	10.02.02.018; 24.12.04.011; 22.01.01.015; 20.05.01.013	0.000035%		Not Available
Rheumatic disorder	15.03.04.018; 10.02.01.048	0.000052%		Not Available
Drug reaction with eosinophilia and systemic symptoms	12.03.01.064; 23.03.05.005; 10.01.01.021	0.000577%		Not Available
Autoimmune haemolytic anaemia	10.04.01.005; 01.06.01.004	0.000035%		Not Available

The 28th Page First Pre 28 29 30 31 32 Next Last Total 36 Pages